Aldéric Fraslin
Inserm(FR)Université Paris-Saclay(FR)Institut Gustave Roussy(FR)La Ligue Contre le Cancer(FR)Centre de recherche en Epidémiologie et Santé des Populations(FR)
Publications by Year
Research Areas
COVID-19 and healthcare impacts, Economic and Financial Impacts of Cancer, Global Cancer Incidence and Screening, Head and Neck Cancer Studies, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial(2021)218 cited
- → Impact of COVID-19 on healthcare organisation and cancer outcomes(2021)184 cited
- → A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial(2021)46 cited
- → Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results of the GORTEC 2014-01 TPExtreme Randomized Trial(2020)13 cited
- → Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life(2023)10 cited